TNF and neoplasm: In addition, we find that systemically applied immunostimulatory agents such as oncolytic VSV or recombinant IFN-α can result in increased TNF-α in the brain to potentially kill tumours with SMCs, releasing tumour antigens and stimulating inflammatory and immunomodulatory responses.